Dyne Therapeutics Inc [DYN] stock is trading at $34.13, up 16.37%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The DYN shares have gain 14.49% over the last week, with a monthly amount glided 1.61%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Dyne Therapeutics Inc [NASDAQ: DYN] stock has seen the most recent analyst activity on October 24, 2024, when JP Morgan downgraded its rating to a Neutral and also revised its price target to $35 from $43. Previously, Chardan Capital Markets reaffirmed its Buy rating on May 21, 2024, and elevated its price target to $42. On April 30, 2024, Morgan Stanley initiated with a Overweight rating and assigned a price target of $40 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $36 on February 20, 2024. Raymond James upgraded its rating to a Strong Buy and raised its price target to $27 on February 27, 2023. Oppenheimer started tracking with a Outperform rating for this stock on February 15, 2023, and assigned it a price target of $34. In a note dated January 26, 2023, Guggenheim initiated an Buy rating and provided a target price of $33 on this stock.
Dyne Therapeutics Inc [DYN] stock has fluctuated between $8.05 and $47.45 over the past year. Currently, Wall Street analysts expect the stock to reach $43.88 within the next 12 months. Dyne Therapeutics Inc [NASDAQ: DYN] shares were valued at $34.13 at the most recent close of the market. An investor can expect a potential return of 28.57% based on the average DYN price forecast.
Analyzing the DYN fundamentals
Gross Profit Margin for this corporation currently stands at 0.49% with Operating Profit Margin at -71.56%, Pretax Profit Margin comes in at -68.0%, and Net Profit Margin reading is -68.0%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.69 and Total Capital is -0.34. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 30.21 points at the first support level, and at 26.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 36.87, and for the 2nd resistance point, it is at 39.60.
Ratios To Look Out For
For context, Dyne Therapeutics Inc’s Current Ratio is 17.02. As well, the Quick Ratio is 17.02, while the Cash Ratio is 20.44.
Transactions by insiders
Recent insider trading involved Kersten Dirk, Director, that happened on Oct 18 ’24 when 13414.0 shares were sold. Director, Kersten Dirk completed a deal on Oct 21 ’24 to sell 121.0 shares. Meanwhile, Director Kersten Dirk sold 23671.0 shares on Oct 16 ’24.
